Detailed Narrative
Strong Financial Performance in FY25
Aarti Pharmalabs reported a landmark FY25 with robust growth across all key financial metrics. Revenue grew 14% YoY to Rs. 2,113 crores, EBITDA increased 20% YoY to Rs. 464 crores, and PAT rose 26% YoY to Rs. 272 crores. The fourth quarter also set a new record for quarterly PAT at Rs. 88 crores, marking a 35% YoY growth, with EBITDA margins expanding to 26% from 23% in Q4 FY24. Net cash from operations for FY25 remained strong at Rs. 332 crores.
Segmental Contributions and Strategic Focus
In Q4 FY25, Xanthine derivatives contributed 34% of turnover, while the API & Intermediate business recorded its highest-ever quarterly sales, accounting for 39% of total turnover. The company's strategic focus on regulated markets within API was evident, with 52% of sales in regulated markets. The CDMO/CMO segment contributed 27% of turnover, with active projects increasing to 61 (from 56 in the previous quarter), including 33 at the commercial stage and 27 in development.
Capacity Expansion and Project Timelines
The Xanthine derivative capacity expansion to 9,000 metric tons is progressing as planned, with phased commissioning estimated in H2 FY26 and full operationalization by Q1 FY27. The greenfield project at Atali is nearing mechanical completion by the end of the current quarter (Q1 FY26), with phased operationalization and full ramp-up anticipated by the end of FY26. This project will add 450 KL of additional capacity, bringing the total capacity to over 1,500 KL.
FY26 Outlook and Growth Drivers
For FY26, the company guides for an EBITDA growth of 12-15% on a standalone basis, supported by higher-margin products, improved process efficiencies, and volume growth. The CDMO/CMO segment is projected to grow 30-40% in FY26, driven by a strong pipeline of 60 products and 21 customers. The company aims for 80-90% utilization of Xanthine capacity within three years, targeting Rs. 1,000-1,250 crores in revenue from this segment.
Capital Expenditure and Debt Profile
Aarti Pharmalabs spent over Rs. 400 crores on CAPEX in FY25 and plans a similar spend of Rs. 400-450 crores in FY26. This includes approximately Rs. 200 crores for the remaining Atali CAPEX and over Rs. 100 crores for Xanthine expansion, along with maintenance and R&D CAPEX (Rs. 40 crores annually for R&D). Total borrowings are currently over Rs. 400 crores, expected to increase by Rs. 100-125 crores in FY26, maintaining a debt-equity ratio of 0.23-0.25.
Sustainability Achievements
The company achieved an EcoVadis Gold Rating, placing it among the top 5% globally for sustainability. It also secured SBTi approval for GHG emission reduction targets across all three scopes, becoming the sixth Indian Pharma CDMO player to do so. These achievements underscore the company's commitment to environmental and social governance.
Ganesh Polychem Business Update
The Ganesh Polychem business experienced a slowdown in overall demand and underwent a 3-4 month facility shutdown for upgrades aimed at achieving a lower-cost production route. This is expected to impact the business's numbers in Q4 FY25 and Q1 FY26. Management anticipates normalization of numbers once the upgraded facility becomes operational.